Manfred Schuster

This inventor holds 17 USPTO granted patents and 7 published patent applications, plus 1 CIPO patent and 16 EPO patents, primarily in Cancer Treatment. Top assignees: Apeiron Biologics Ag, Greenovation Biotech Gmbh, Attoquant Diagnostics Gmbh. Active years: 2010-2022.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Manfred Schuster. Retrieved from https://idiyas.com/inventor/manfred-schuster

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 17 (Patent Applications = 7)

% Patents Active = 88.2

CIPO Patents = 1 (Patent Applications = 1)

EPO Patents = 16 (Patent Applications = 18)

Average Co-Inventor Count = 4.7

ph-index = 4

Forward Citations = 34(Granted Patents)

Location History:

Schrick, AT (2010 - 2019)
Vienna, AT (2017 - 2022)

Company Filing History:

Greenovation Biotech Gmbh

patents

2 out of 5

Attoquant Diagnostics Gmbh

patents

4. 2 out of 2

Meridian Biopharmaceuticals Gmbh

patents

5. 1 out of 1

Apeiron Biologicals Ag

patent

6. 1 out of 1

Apeiron Biologics Forschungs-Und Entwicklungsgesellschaft M.b.h.

patent

7. 1 out of 3

Igeneon Krebs-Immuntherapie Forschungs-Und Entwicklungs-Ag

patents

8. 1 out of 12

Medical University of Innsbruck

patents

9. 1 out of 834,570

Other

patents

where one patent can have more than one assignee

Years Active: 2010-2022

Loading Chart...

Areas of Expertise:

GD2 Positive Cancer

Peptidic Degradation Products

ACE2 Polypeptide

Glyco-Engineered Antibodies

Inflammatory Illnesses

SiRNA

Immunoreactivity

Recombinant Antibody

N-Glycosylated Antibody

Tumor Treatment

Proteolytic Cascade

Lewis Y-Expressing Tumors

17 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11447565 - Method for treating a GD2 positive cancer (2022-09-20),

2. 11079398 - Method for measurement of peptidic degradation products of a proteolytic cascade in blood samples (2021-08-03),

3. 10716833 - Method for producing ACE2 polypeptide (2020-07-21),

4. 10253098 - Glyco-engineered antibodies (2019-04-09),

5. 9777068 - Method for treating a GD2 positive cancer (2017-10-03),

6. 9757433 - Modified ACE2 polypeptides (2017-09-12),

7. 9684004 - Method for measurement of peptidic degradation products of a proteolytic cascade in blood samples (2017-06-20),

8. 9561263 - Treatment of inflammatory illnesses with ACE2 (2017-02-07),

9. 9186373 - SiRNA against Cbl-b and optionally IL-2 and IL-12 for use in the treatment of cancer (2015-11-17),

10. 9051577 - Glyco-engineered antibodies (2015-06-09),

11. 8946162 - Treatment of tumors (2015-02-03),

12. 8809288 - Method for increasing immunoreactivity (2014-08-19),

13. 8586319 - Recombinant ACE2 polypeptide dimer (2013-11-19),

14. 8323650 - Method of treating lewis Y-expressing tumors (2012-12-04),

15. 8241864 - Method for determining ACE2 activity (2012-08-14),

Title: Manfred Schuster: Innovator in Cancer Treatment and Biotech

Introduction

Manfred Schuster is a prominent inventor based in Schrick, Austria. He has made significant contributions to the field of biotechnology, particularly in cancer treatment. With a total of 17 patents to his name, Schuster's work has the potential to impact the lives of many patients.

Latest Patents

Among his latest patents is a method for treating GD2 positive cancer. This innovative approach involves administering a preparation comprising an anti-GD2 antibody to a patient as a continuous intravenous infusion over 24 hours per day. Another notable patent focuses on the measurement of peptidic degradation products of a proteolytic cascade in blood samples. This invention discloses a method for measuring these degradation products in biological samples, especially blood samples, by incubating the sample until a steady state equilibrium is reached.

Career Highlights

Throughout his career, Schuster has worked with several notable companies, including Apeiron Biologics AG and Greenovation Biotech GmbH. His experience in these organizations has allowed him to develop and refine his innovative ideas in the biotech sector.

Collaborations

Some of his notable coworkers include Hans Loibner and Evelyne Janzek-Hawlat. Their collaboration has contributed to the advancement of research and development in the field.

Conclusion

Manfred Schuster's contributions to biotechnology and cancer treatment through his patents and collaborations highlight his role as an influential inventor. His work continues to pave the way for advancements in medical science.

Profile summary based on public USPTO records.